Evonik Holds the Line on BASF as Jefferies Trims Its Rating but Lifts Its Target
Published on 11/16/2026 at 08:40 | Editorial boerse-global.deEvonik has turned down BASF's takeover approach once more, sticking to its refusal even after the chief executives and finance chiefs of both companies sat down together. Reuters, citing a person familiar with the matter, reported on 9 November that no further meetings were on the calendar at that stage. The board-level talks, in other words, produced no green light for the bid.
That rebuff came alongside a fresh piece of broker news. Jefferies cut Evonik to "Hold" from "Buy" on 10 November, while at the same time raising its price target to 21 euros from 20 euros. The higher target and the softer recommendation arrived as a pair, and the downgrade carried a notable trim to forecasts: the analysts lowered their 2027 EBITDA estimate by 9% to below 2 billion euros.
A Target Below the Market
The stock's own performance quickly put Jefferies' number in the rear-view mirror. On Friday, Evonik shares added 0.9% to close at €21.14, leaving the closing price above the target the broker had just set. Investors, it seems, were not reading the downgrade as a reason to head for the exits.
On the operational side, Evonik had a busy few days. On 10 November the company reported the first GMP-grade batch of its PhytoChol® lipid, produced at the new Lipid Innovation Center in Lafayette, Indiana. Full capacity at the site is expected to be available from mid-2027, according to the company.
Should investors sell immediately? Or is it worth buying Evonik?
The same day brought word of a completed 52 million euro investment in Essen, where Evonik has expanded its silicone platform with a new production facility and a tank farm.
AI Takes the Controls at Oxeno
Process technology was the theme at Evonik Oxeno, which said on 9 November that it had brought AI-based process models into live plant operations for the first time. The initial applications are expected to improve energy efficiency and cut CO? emissions, the company said.
Evonik also used 9 November to flag its presence at EuroTier 2026 in Hanover, where it plans to showcase new specialty nutrition solutions during the 10–13 November trade fair, including Lypron® and ZyneXtra™.
Evonik at a turning point? This analysis reveals what investors need to know now.
Taken together, the picture is of a company pressing ahead with its standalone strategy — expanding production, wiring artificial intelligence into its plants and rolling out new products — while politely but firmly keeping BASF at arm's length. Whether the market's confidence, which has already carried the shares past Jefferies' revised target, proves justified is a question the coming quarters will have to answer.
Ad
Evonik Stock: New Analysis - 16 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
